SCHEMBL4537672

SCHEMBL4537672

O=C(CC(=O)Oc1ncc(Cl)cc1Cl)Oc1ncc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
TSHR P16473 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CYP2C9 P11712 1/20 0.49
APEX1 P27695 1/20 0.49
LIPE Q05469 4/20 0.47
BCHE P06276 1/20 0.47
MAPK1 P28482 2/20 0.46
L3MBTL1 Q9Y468 8/20 0.45
PSMB5 P28074 1/20 0.42
NR4A1 P22736 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
F2 P00734 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4537676 0.92 L3MBTL1 (0.49) LMNATSHRSMN1; SMN2CYP2C9APEX1
SCHEMBL4530859 0.83 ACACB (0.38) LMNALIPEBCHEL3MBTL1HPGD
SCHEMBL3998742 0.81 LMNA (0.52) LMNATSHRSMN1; SMN2CYP2C9APEX1
SCHEMBL4947714 0.80 LMNA (0.50) LMNATSHRSMN1; SMN2CYP2C9APEX1
SCHEMBL10435485 0.77 L3MBTL1 (0.46) LMNATSHRSMN1; SMN2CYP2C9APEX1
SCHEMBL4530860 0.76 LMNA (0.40) LMNALIPEBCHEL3MBTL1
SCHEMBL11000247 0.75 TDP1 (0.53) LMNATSHRSMN1; SMN2CYP2C9APEX1
SCHEMBL29243800 0.75 L3MBTL1 (0.52) LMNATSHRSMN1; SMN2CYP2C9APEX1
SCHEMBL27870448 0.75 S1PR1 (0.43) TSHRLIPEBCHEL3MBTL1RAB9A
SCHEMBL27692769 0.73 LIPE (0.50) LMNATSHRSMN1; SMN2CYP2C9APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258136-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-04 US disclosed
US-20090275589-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-05 US disclosed
EP-1958946-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275589-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, PDXK LMNA 2869/4885TSHR 2386/4885SMN1; SMN2 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.